论文部分内容阅读
目的获取过敏性疾病患儿疾病、生活质量相关资料,并观察孟鲁司特治疗儿童过敏性疾病的疗效。方法 2008年3月至2011年5月北京第二炮兵总医院59例过敏性疾病患儿,分两组:对照组28例,按原发病常规治疗;治疗组31例,在常规治疗基础上加服孟鲁司特(5mg/d,晚睡前服),疗程3～6个月。6个月后,分别对两组及治疗组治疗前后过敏原点刺结果、临床症状、体重、心理行为、学习成绩5项指标进行评估。结果对照组与治疗组临床症状均明显改善;治疗后对照组与治疗组低体重、行为异常、学绩低分发生率分别为53.6%、38.7%,50.0%、25.8%和64.3%、41.9%,其中行为异常发生率组两组间差异有统计学意义(P<0.05)。治疗组治疗前后,低体重(≤P25)、行为异常、学绩低分发生率分别为83.9%、38.7%,74.2%、25.8%和80.6%、41.9%,差异均有统计学意义(P<0.05)。结论儿童过敏性疾病常为心身共患疾病,孟鲁司特治疗儿童过敏性疾病有效,临床综合评估更能反应临床疗效。
Objective To obtain the data of disease and quality of life in children with allergic diseases and to observe the curative effect of montelukast on children with allergic diseases. Methods From March 2008 to May 2011, 59 children with allergic diseases from the Second Artillery General Hospital of Beijing were divided into two groups: control group (n = 28), routine treatment according to primary disease; treatment group (n = 31) Add montelukast (5mg / d, night before bedtime), course of treatment of 3 to 6 months. Six months later, the allergens prick results, clinical symptoms, weight, psychological behavior and academic performance were evaluated before and after treatment in both groups and the treatment group. Results The clinical symptoms of the control group and the treatment group were significantly improved. After treatment, the prevalences of low weight, abnormal behavior and low grades in the control group and the treatment group were 53.6%, 38.7%, 50.0%, 25.8% and 64.3%, 41.9% The difference between the two groups was statistically significant (P <0.05). Before and after treatment, the incidences of low weight (≤ P25), abnormal behavior and low academic achievement were 83.9%, 38.7%, 74.2%, 25.8% and 80.6%, 41.9% in the treatment group, respectively, with significant differences (P < 0.05). Conclusions Childhood allergic diseases are often psychosomatic diseases, montelukast is effective in treating children with allergic diseases, and clinical comprehensive evaluation can better reflect the clinical curative effect.